Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings [PDF]
Introduction: SARS-CoV-2 is now endemic and expected to remain a health threat, with new variants continuing to emerge and the potential for vaccines to become less effective.
Andrew, Melissa +23 more
core +2 more sources
A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments [PDF]
Objective: Unusual clinical course Background: SARS-CoV-2 infection can persist in immunocompromised patients with hematological malignancies, despite antiviral treatment.
Cingolani, Antonella +8 more
core +1 more source
Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019
VirusesAlthough the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat to the immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance to severe
Chie Yamamoto +13 more
doaj +1 more source
High Throughput Screening and Molecular Docking Analysis on DNA Polymerase (Pol) Β Cancer Variant K289M [PDF]
DNA polymerase (pol) β plays a critical role in DNA repair mechanisms, and mutations in this enzyme have been implicated in various cancers. Because it may play a role in oncogenesis by altering the fidelity of DNA synthesis, the K289M variation of pol β
Kumar, Nitanshu +3 more
core +2 more sources
Deriving M-polynomial Based Topological Descriptors of Oral Antiviral Clinical Drug Nirmatrelvir
Scientific Annals of Computer ScienceThe novel human coronavirus known as SARS-CoV-2 poses a serious risk to human health. Regretfully, the US Food and Drug Administration (FDA) has approved very few oral antiviral medications for the treatment of COVID-19 patients. In the current study, we
Shibsankar Das, Modhuleena Mandal
doaj +1 more source
Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA [PDF]
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a monovalent component of the XBB.1.5 variant “to provide ...
Duggal, Abhijit +4 more
core +2 more sources
Nirmatrelvir-ritonavir for COVID-19 [PDF]
Canadian Medical Association Journal, 2022 McDonald, Emily G, Lee, Todd C
openaire +2 more sources
Infection and Drug ResistanceNa Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N +9 more
doaj
In Vitro Screening of Anti-Viral and Virucidal Effects Against SARS-CoV-2 by Phenylamino-Phenoxy-Quinoline Derivatives: An Integrative Computational Approach [PDF]
This study investigated the binding interactions between three groups of 2,4-disubstituted phenylamino-phenoxyquinoline derivatives 1-3(a-d) and four readily available drugs (ritonavir, ensitrelvir, nirmatrelvir, and paxlovid) with severe acute ...
Baicharoen, Apisara +9 more
core +1 more source
In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach [PDF]
, 2022 Bartha Ferenc Ágoston +4 more
core +1 more source